This article provides financial information for Karman Holdings Inc. (MUN:VF4), specifically its enterprise value to EBIT forward. It indicates that the market is closed with no trades and lists various tools and services offered by TradingView alongside copyright information for the data sources.

Boston Scientific (BSX) stock dropped 1.84% on the latest closing session despite broader market gains, with the S&P 500 up 0.79%. The medical device manufacturer has seen a 9.38% decline in the past month, underperforming its sector and the S&P 500. Investors are anticipating its upcoming earnings report on July 29, 2026, where analysts expect year-over-year growth in both earnings per share and revenue.

Extra Space Storage Inc. (NYSE: EXR) announced it will release its financial results for the second quarter of 2026 on Tuesday, July 28, 2026, after market close. The company will host a conference call on Wednesday, July 29, 2026, at 1:00 p.m. Eastern Time, featuring CEO Joe Margolis, President Noah Springer, and CFO Jeff Norman, to discuss the results and recent events. Registered financial analysts will participate in a Q&A session, while other attendees can listen only.

Kratos Defense & Security Solutions Inc (KTOS) saw its stock rise by 6.2% to $49.86, despite a 22.2% drop over the last month. GuruFocus's GF Value rates KTOS as "Significantly Overvalued" at $49.86 compared to its intrinsic value of $28.10, indicating a limited margin of safety for investors. The company has a strong GF Score of 80/100, driven by high financial strength and growth, but its valuation score is low, further supported by $11.7 million in insider stock sales over the past three months.

Wedbush has initiated an Outperform rating for Kratos Defense & Security Solutions (KTOS) with an $85 target price, recognizing its crucial role as a defense sector supplier. Despite a high P/E ratio of 293.29x indicating strong growth expectations and a GF Score of 80/100, the company faces challenges in profitability and has seen significant insider selling worth $11.7 million in the last three months. This presents a mixed outlook for investors, balancing strong potential with high valuation and insider divestment.

This article provides a brief financial overview of Korea Fund Inc (LSX:A0REA4) on the Lang & Schwarz Exchange, specifically focusing on its price to book forward metric. It indicates that the market was closed with no trades at the time of publication and lists standard financial data providers.

Eugene Schneider, EVP and Chief Clinical Development Officer at Ionis Pharmaceuticals, sold 26,000 shares of company stock for over $2.1 million, following the exercise of stock options. This transaction occurred amidst a 101% stock return over the past year, though InvestingPro analysis indicates the stock may be overvalued. The sale happened shortly after the company received FDA approval for its drug Tryngolza and appointed a new director.

The spouse of Ionis Pharmaceuticals EVP Joseph Baroldi sold 5,635 shares of common stock for $451,698 on June 26, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high, although InvestingPro analysis suggests it may be overvalued. Concurrently, Mr. Baroldi’s spouse also acquired 5,635 shares through option exercises, and the company recently received FDA approval for its drug Tryngolza, leading to positive analyst ratings.

This article reports on the filing of Form 4 by Ionis Pharmaceuticals Inc. for the period ending June 30. It provides a brief financial update on the company's stock performance. The article is very concise, primarily serving as an announcement of the filing.

Jefferies, a Wall Street investment bank, is expanding its office in The Crescent in Uptown Dallas. This move reflects the firm's confidence in the growing dealmaking activity, increasing IPOs, and corporate relocations to North Texas, trends executives believe will continue. The expansion signifies Jefferies' commitment to the "Y'all Street" momentum in Dallas.